Dr. Haas is Chairman of the Department of Radiation Oncology at NYU-Long Island Hospital and Professor of Radiation Oncology at the NYU Long Island School of Medicine. Dr. Haas was one of the first radiation oncologists to perform prostate SBRT and has amongst the world’s largest clinical experience. He is a reviewer and editor of many preeminent journals and serves as the genitourinary oncology site leader for the Radiosurgery Society.

Dr. Blacksburg is the Global Chief Medical Officer of Accuray, Inc. He previously served as the Chair of Radiation Medicine at Lenox Hill Hospital and Associate Professor of Radiation Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. He was the Associate Director of Radiation Oncology at NYU-Long Island Hospital and the Medical Director of the NYCyberknife Facility. Dr. Blacksburg has an expertise involving the use of SBRT to treat prostate cancer and has lectured and presented a wide body of research on the international stage. He is an expert in medical informatics and health sector management.

Dr. Yang is a prominent medical physicist with a distinguished career spanning multiple roles and countries. He served as the Chief Physicist at Philadelphia CyberKnife, and held a position as an adjunct clinical Associate Professor at Drexel University. Currently, Dr. Yang is with Junxin Oncology Group & Foshan Chancheng Hospital in China, where he continues to contribute to the field of medical physics, particularly in radiosurgery. His extensive experience includes managing thousands of SRS/SBRT cases and authoring numerous publications focused on radiosurgery physics, radiobiology, and clinical outcomes. He is a highly sought out global thought leader.

Dr. Collins is the Director of the Cyberknife Prostate Program at MedStar Georgetown University Hospital and an Associate Professor of Radiation Medicine at Georgetown University School of Medicine. Dr. Collins has published extensively on outcomes and quality of life as it relates to prostate SBRT and is a frequent international lecturer. He serves as a reviewer and editorial board member for numerous medicine and oncology journals and, has amongst the highest volume of Prostate SBRT manuscripts published to-date. He has been nicknamed “The Oracle” on prostate SBRT Quality of Life

Dr. Freeman is a pioneer in the use of prostate SBRT, having treated patients in a community setting for over 20 years. In 2004, Dr. Freeman introduced CyberKnife Robotic Radiosurgery in Naples, Florida, and co-developed the first community-based prostate radiosurgery program in the United States, and gained national recognition as a leader in the field. She continues to develop and promote radiosurgical technologic expertise on both the local and national stage. In 2010, She co-founded the Registry for Prostate Cancer Radiosurgery. This database was used to support Medicare coverage of prostate radiosurgery nationwide. She is a Board Member of the CyberKnife Coalition.

Dr. Lee Goddard is a highly accomplished medical physicist at the Albert Einstein College of Medicine. His extensive publications and presentations focus on advanced radiation therapy techniques, particularly in the realms of stereotactic radiosurgery, stereotactic body radiation therapy, and novel, adaptive radiotherapy treatment approaches. His research has included investigations on enhancing the precision of prostate radiation dose delivery through advanced motion compensation, allowing for reduced PTV margins.

Dr. Lepor is a Professor and the Martin Spatz Chairman of the Department of Urology at NYU Grossman School of Medicine, where he has propelled the department into the top ranks nationally. An esteemed leader in Urology and Uro-Oncology, he has authored over 400 peer-reviewed articles and numerous books, focusing on prostate cancer and benign prostatic hyperplasia. His pioneering research includes co-developing nerve-sparing radical prostatectomy techniques and advancing the use of multiparametric MRI in urology. Dr. Lepor's numerous accolades include the prestigious Gold Cystoscope Award from The American Urological Association.

Dr. Roach is a Professor of Radiation Oncology and Urology at the University of California San Francisco. He is recognized as an authority on the treatment of localized prostate cancer with extensive publications on the subject. Dr. Roach was a leader in establishing the American College of Radiology (ACR) Appropriateness Criteria Guidelines for prostate cancer from 1996 through 2006. He has served on numerous editorial boards and was appointed (2013) by President Obama to serve on a 6-year term on the National Cancer Advisory Board, involved in defining the research agenda for our nation.

Dr. Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University. He is an international expert in the management of prostate cancer and the development and validation of prognostic and predictive biomarkers. He serves as the Chair for NRG Oncology's Intact Prostate Cancer Subcommittee, and for the National Cancer Institute's Genitourinary Steering Committee. He is the PI of numerous national and international randomized clinical trials in prostate and bladder cancer.

Dr. Stock is a Professor of Radiation Oncology at the Icahn School of Medicine at Mount Sinai. An early pioneer of modern prostate brachytherapy, Dr. Stock authored critical publications involving optimal management of prostate malignancy with dose-escalated radiation therapy. He has served on the board of American College of Radiology Testing and the American Brachytherapy Society, where he is member at large, and as guest editor of a special Brachytherapy issue of Techniques in Urology.

Dr. Timmerman is Professor and Chair of Radiation Oncology, Professor of Neurosurgery, and Effie Marie Cain Distinguished Chair in Cancer Therapy Research at UT Southwestern Medical Center. He was the principal investigator or co-investigator on several prospective trials that helped determine efficacy and toxicity of stereotactic body radiation therapy in lung, liver, spine, and pelvic sites.

Professor Tome is a Professor of Radiation Oncology and Neurology, as well as the Director of Medical Physics at the Institute for Onco-Physics at the Albert Einstein College of medicine. He is renowned for his impactful work in medicine, particularly in high-precision radiation therapy techniques like photogrammetry, risk adaptive therapy, and hippocampal avoidant cranial radiation to protect neurocognitive functions. He has authored significant texts in medical and mathematical physics, published over 275 articles, co-invented novel Gadolinium-based agents for tumor imaging and therapy, and holds 10 patents.

Professor van As is Consultant Clinical Oncologist and Medical Director of The Royal Marsden and Professor of The Institute of Cancer Research. Professor van As was previously Chair of the UK SBRT Consortium and is the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer, which has helped define the standard of care for prostate SBRT

Dr. Witten, is the chief physicist in the Department of Radiation Oncology at NYU Long Island School of Medicine and Director of the Division of CyberKnife Radiosurgery. He is an Associate Professor at the NYU Grossman School of Medicine. Dr. Witten studies the application of biologically-inspired computational intelligence methods to optimization problems in radiation therapy, including treatment planning optimization, methods of comparing planned and measured dose distributions via dose map warping, and synthetic CT generation. He regularly serves as a technical reviewer for IEEE Computational Intelligence conferences.

Professor Wu is a Professor of Radiation Oncology at the CyberKnife Center of Miami, University of Miami Miller School of Medicine, and serves as the President and CEO of Executive Medical Physics Associates. Renowned for his pioneering work in the field of medical physics, Dr. Wu has been a primary author on research focusing on the technical and clinical implementation of Lattice Radiation Therapy (LRT). His expertise has significantly advanced radiation therapy techniques, enhancing both the theoretical framework and practical applications in cancer treatment. Dr. Wu’s leadership and scholarly activities continue to influence the global landscape of medical physics and radiation oncology.

Dr. Zelefsky is Vice Chair and the Director of Brachytherapy Services in the Department of Radiation Oncology at NYU Grossman School of Medicine. He serves as the Editor-in-Chief of the journal, Brachytherapy, and has published extensively on the management of prostate cancer. Dr. Zelefsky helped pioneer the use of IMRT, IGRT, SBRT in the treatment of men with prostate cancer and is a seminal voice in managing prostate malignancy.